|国家科技期刊平台
首页|期刊导航|中国药科大学学报|间充质干细胞产品及其外泌体在炎症性肠病治疗中的研究进展

间充质干细胞产品及其外泌体在炎症性肠病治疗中的研究进展OA北大核心CSTPCD

Research progress on mesenchymal stem cell products and their exosomes in the treatment of inflammatory bowel disease

中文摘要英文摘要

炎症性肠病(inflammatory bowel disease,IBD)发病机制不明,特征为进行性和终身复发性消化道炎症反应.尽管现阶段新的治疗药物和策略不断涌现,但治疗作用局限于单一的抗炎功能,在复杂黏膜免疫环境下易出现耐药导致治疗失败.间充质干细胞(mesenchymal stem cells,MSCs)能定向归巢到结肠炎症部位,具有强大的免疫调节能力,可重塑肠道免疫环境和修复上皮屏障,为药物难治性患者的治疗提供了极具潜力的替代方案.本文对MSCs产品及其衍生的外泌体在临床上的应用、作用机制和工程化进行综述,以期为MSCs及其外泌体产品用于IBD的治疗提供参考.

Inflammatory bowel disease(IBD),whose pathogenesis remains elusive,is a group of autoimmune diseases characterized by chronic,progressive,and lifelong inflammation of the digestive tract.The pathogenesis of IBD remains elusive.Although a number of drugs have been developed to treat IBD,their effects are merely anti-inflammatory.In addition,current treatments for IBD are easily susceptible to resistance in clinical practice.Mesenchymal stem cells(MSCs)have been reported to have the ability to migrate to the site of inflammation,with potent immunoregulatory effects,and to rebalance the immune microenvironment and restore the integrity of the epithelial barrier with significant value of application,particularly for patients who are refractory to classic medicines.In this paper,we reviewed the clinical applications,mechanisms and engineerable properties of MSC products and their exosomes to provide some reference for the use of MSCs and their exosomes in the treatment of IBD.

杨婧雯;陈芊;单云龙;刘嘉莉;尉宁;王婧;王广基;周芳

中国药科大学药物代谢动力学重点实验室, 南京 210009中国药科大学药物代谢动力学重点实验室, 南京 210009||江苏睿源生物技术有限公司, 南京 211103江苏睿源生物技术有限公司, 南京 211103

临床医学

炎症性肠病间充质干细胞外泌体工程化

inflammatory bowel diseasemesenchymal stem cellsexosomesengineering

《中国药科大学学报》 2024 (001)

干细胞药物治疗狼疮性肾炎的PK-PD及其调控机制研究

103-114 / 12

国家自然科学基金项目(No.82073928);南京市生命健康科技专项(No.202110006);细胞生态海河实验室创新基金项目(22HHXBSS00005);江苏省南京市联合资助项目(SBK2023070039)This study was supported by the National Natural Science Foundation of China(No.82073928);the Nanjing Life and Health Science and Technology Program(No.202110006);the Haihe Laboratory of Cell Ecosystem Innovation Fund(22HHXBSS00005);and the Co-funded Programs in Nanjing,Jiangsu Province(SBK2023070039)

10.11665/j.issn.1000-5048.2023113001

评论